Androgen dynamics and serum PSA in patients treated with abiraterone acetate

BACKGROUND: We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline in metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS: COU-AA-30...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, C J, Peng, W, Kheoh, T, Welkowsky, E, Haqq, C M, Chandler, D W, Scher, H I, Molina, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020277/
https://www.ncbi.nlm.nih.gov/pubmed/24637537
http://dx.doi.org/10.1038/pcan.2014.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020277/
https://www.ncbi.nlm.nih.gov/pubmed/24637537
http://dx.doi.org/10.1038/pcan.2014.8

Ejemplares similares